South San Francisco, CA, November, 30, 2020– FlemingMartin is pleased to announce that Global Blood Therapeutics (NASDAQ: GBT) has hired Cora Versaggi as Executive Director, Human Resources Business Partner & Talent Development Lead. GBT is a biopharmaceutical company committed to helping underserved patient communities by revolutionizing the treatment of severe blood-based conditions starting with Sickle Cell Disease (SCD). GBT’s Oxbryta is the first treatment approved by the FDA to target an underlying cause of SCD.
At GBT, Cora will partner closely with the Commercial, Medical Affairs, and G&A functions as the business scales globally, plus she will play a pivotal role in companywide talent development initiatives. Cora possesses deep HRBP expertise from her 16 years at BioMarin Pharmaceuticals. At BMRN, Cora held a broad spectrum of HR leadership positions as the Company scaled from fewer than 300 to nearly 3,500 employees. Cora earned her Bachelor’s degree in Business Administration from San Diego State University.
Global Blood Therapeutics (GBT) is working to discover, develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease (SCD). GBT’s Oxbryta is the first treatment approved by the FDA to target an underlying cause of SCD.
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity/Venture Capital Firms, and CEOs to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.